Małek Robert, Borowicz Kinga K, Kimber-Trojnar Zanta, Sobieszek Grzegorz, Piskorska Barbara, Czuczwar Stanisław J
Department of Pathophysiology, Medical University, Jaczewskiego 8, PL 20-090 Lublin, Poland.
Pol J Pharmacol. 2003 Sep-Oct;55(5):691-8.
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is to keep the patient free of seizures without interfering with normal brain function. Unfortunately, about 30% of all epilepsies remain without control. In this situation patients require polytherapy which is usually a combination of antiepileptic drugs (AEDs) acting via different mechanisms of action. Many potential AEDs have been developed but the proportion of patients failing to respond to drug treatment has not been fundamentally changed. The aim of this review was to assemble current literature data on remacemide, a novel AED, which is suggested for the treatment of epilepsy. Remacemide hydrochloride is a low-affinity NMDA receptor blocker as well as Na(+) fast-channel blocker. The drug exerts anticonvulsant activity both in various animal seizure models and in clinical studies. In addition to its antiseizure properties, the drug seems to provide neuroprotection. Remacemide holds promise to serve as neuroprotectant not only in seizures but perhaps in other neurodegenerative conditions in humans as well.
癫痫属于常见的脑部疾病。它影响着约1%的人口。癫痫治疗的目的是使患者在不干扰正常脑功能的情况下无癫痫发作。不幸的是，所有癫痫患者中约有30%仍未得到控制。在这种情况下，患者需要联合治疗，通常是联合使用通过不同作用机制发挥作用的抗癫痫药物（AEDs）。已经研发出许多潜在的抗癫痫药物，但对药物治疗无反应的患者比例并未从根本上改变。本综述的目的是收集有关新型抗癫痫药物瑞玛西胺的现有文献数据，该药物被推荐用于癫痫治疗。盐酸瑞玛西胺是一种低亲和力的N-甲基-D-天冬氨酸（NMDA）受体阻滞剂以及钠离子快速通道阻滞剂。该药物在各种动物癫痫模型和临床研究中均发挥抗惊厥活性。除了其抗癫痫特性外，该药物似乎还具有神经保护作用。瑞玛西胺有望不仅在癫痫发作中，而且可能在人类的其他神经退行性疾病中作为神经保护剂发挥作用。
